A federal judge gave subpoena power to the controversial claims administrator for the BP Gulf oil spill settlement. (WDSU)
Amarin Pharma is preemptively challenging the FDA’s rules on off-label marketing of drugs, alleging that they violate the First Amendment (New York Times)
To sign up to receive our email with updates on Legal Reform, fill in the following fields. When you hit submit, you consent to our processing of the personal data you provide us with. Thanks and welcome.
Before submitting your personal data, please take a look at our Privacy Notice: General Privacy Notice orEU Privacy Notice. You can also contact us at privacy@uschamber.com.
